Last mentioned: Feb 24, 2026
Patent Extension
Secured Rezdiffra patent protection through 2045.
DGAT-2 and siRNA Expansion
Acquired late-stage DGAT-2 inhibitor and six preclinical siRNA assets.
GLP-1 Acquisition
Madrigal paid $120 million upfront to acquire an oral GLP-1 program.
Rezdiffra Commercial Launch
First full year of Rezdiffra availability in the U.S. market for MASH.
Madrigal Pharmaceuticals reported a transformative 2025, with Rezdiffra net sales reaching $958.4 million during its first full year on the market. The company is aggressively pivoting toward a multi-asset metabolic powerhouse, integrating oral GLP-1 and DGAT-2 programs alongside its core MASH franchise.
The Q4 2025 earnings cycle reveals a retail landscape defined by digital efficiency and premiumization, with Carvana and Freshpet posting double-digit volume growth. Companies are increasingly leveraging loyalty ecosystems and strategic partnerships to drive margins in a stabilizing consumer market.